echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > FDA approves expansion of Sanofi long-acting insulin glargine injection Toujeo

    FDA approves expansion of Sanofi long-acting insulin glargine injection Toujeo

    • Last Update: 2020-06-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, the U.SFDA(http://approved the extension of Sanofi's(http://'s long-acting insulin glargine injection Toujeo for the treatment of children and adolescents with type 1 diabetes ages 6 and olderabout Toujeo
    Toujeo, a long-acting insulin injection with three times the standard 1mL insulin (100 units/mL), was approved by the FDA in 2015The main activity of insulin is to regulate glucose metabolism, by stimulating peripheral glucose intake, especially the skeletal muscle and fat intake of glucose, and by inhibiting the production of glucose in the liver to achieve the effect of lowering blood sugarThis approval is based primarily on the results of atest(http://called EDITION JUNIORThe trial was designed to test Toujeo's efficacy in treating people with type 1 diabetes between the ages of 6 and 17The results showed that after six months of treatment, patients in the Toujeo treatment group met the non-performance criteria for reducing glycated hemoglobin levels (HbA1c) to the main end of the study, compared to Toujeo Gla-100The incidence of ketones and severe hypoglycemia (54 mg/dL) in this group of patients was relatively low and had the effect of managing blood sugar fluctuations
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.